Investigators employed RNA sequencing of renal cell carcinoma (RCC) patients from two cohorts treated with immune checkpoint inhibitor and tyrosine kinase inhibitors. They utilized immunohistochemistry alongside flow cytometry, aiming at assessing immune cell infiltration and functionality in high-risk localized RCC samples.
[Cellular Oncology]
